Real-time three-dimensional (3D) reconstruction of real-world environments has many significant applications in various fields, including telepresence technology. When depth sensors, such as those from Microsoft's Kinect series, are introduced simultaneously and become widely available, a new generation of telepresence systems can be developed by combining a real-time 3D reconstruction method with these new technologies. This combination enables users to engage with a remote person while remaining in their local area, as well as control remote devices while viewing their 3D virtual representation. There are numerous applications in which having a telepresence experience could be beneficial, including remote collaboration and entertainment, as well as education, advertising, and rehabilitation. The purpose of this systematic literature review is to analyze the recent advances in 3D reconstruction methods for telepresence systems and the significant related work in this field. Next, we determine the input data and the technological device employed to acquire the input data, which will be utilized in the 3D reconstruction process. The methods of 3D reconstruction implemented in the telepresence system as well as the evaluation of the system, have been extracted and assessed from the included studies. Through the analysis and summarization of many dimensions, we discussed the input data used for the 3D reconstruction method, the real-time 3D reconstruction methods implemented in the telepresence system, and how to evaluate the system. We conclude that real-time 3D reconstruction methods for telepresence systems have progressively improved over the years in conjunction with the advancement of machines and devices such as Red Green Blue-Depth (RGB-D) cameras and Graphics Processing Unit (GPU).
Thioredoxin interacting protein (TXNIP) has emerged as a significant regulator of β-cell mass and loss, rendering it an attractive target for treating diabetes. We previously showed that Shiga-Y6, a fluorinated curcumin derivative, inhibited TXNIP mRNA and protein expression in vitro, raising the question of whether the same effect could be translated in vivo. Herein, we examined the effect of Shiga-Y6 on TNXIP levels and explored its therapeutic potential in a mouse model of diabetes, Akita mice. We intraperitoneally injected Shiga-Y6 (SY6; 30 mg/kg of body weight) or vehicle into 8-week-old Akita mice for 28 consecutive days. On day 29, the mice were euthanized, following which the serum levels of glucose, insulin, and glucagon were measured using ELISA, the expression of TXNIP in pancreatic tissue lysates was determined using western blotting, and the level of β-cell apoptosis was assessed using the TUNEL assay. TXNIP levels in the pancreatic tissue of Akita mice were significantly elevated compared with wild-type (WT) mice. Shiga-Y6 administration for 28 days significantly lowered those levels compared with Akita mice that received vehicle to a level comparable to WT mice. In immunohistochemical analysis, both α- to β-cell ratio and the number of apoptotic β-cells were significantly reduced in SY6-treated Akita mice, compared with vehicle-treated Akita mice. Findings from the present study suggest a potential of Shiga-Y6 as an antidiabetic agent through lowering TXNIP protein levels and ameliorating pancreatic β-cells apoptosis.